Merck Updates Vioxx Legal Saga

"As the number of Vioxx-related cases mounts, Merck (MRK:NYSE - commentary - research) is discovering that some of its insurers don't want to pay for the company's defense against the lawsuits. Merck says it will fight the insurers' efforts to reduce or eliminate coverage." [TheStreet.com]